AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2510286
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Placebo
Trial: 19004198
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Jiaji L4‐S1, Waiqiu (GB 36), Weizhong (BL 40), Xiaxi (GB 43) plus intervention injection of Gegensu Zhusheye (Puerarin Injectio)
Trial: 19004198
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture combined with injection of Gegensu Zhusheye (Puerarin Injectio) into Ashi points
Trial: 16600840
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention and referral to a nutritionist (from the beginning of olanzapine treatment in 9 patients)
Trial: 16600840
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention and referral to a nutritionist (from the 9th week of therapy in 8 patients)
Trial: 8970048
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg betamethasone + 4 cm3 of 1% lidocaine
Trial: 8970048
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg betamethasone + 4 cm3 of 1% lidocaine
Trial: 8970048
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg betamethasone + 4 cm3 of 1% lidocaine
Trial: 1420996
Drug: IL-1ra (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra (1 mg/kg)
Trial: 1420996
Drug: IL-1ra (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra (10 mg/kg)
Trial: 1420996
Drug: IL-1ra (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra (1 mg/kg and 10 mg/kg)
Trial: 22403770
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention
Trial: 27785375
Drug: Bepotastine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepotastine 10 mg tablets
Trial: 22691101
Drug: Agrippal® (trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agrippal® (trivalent vaccine)
Trial: 22691101
Drug: Fluvirin® (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvirin® (control trivalent vaccine)
Trial: 20130863
Drug: Prophylactic levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day)
Trial: 20130863
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative LT4 treatment
Trial: 20130863
Drug: Prophylactic levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-deficient patients
Trial: 20130863
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative LT4 treatment among iodine-deficient patients
Trial: 20130863
Drug: Prophylactic levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-sufficient patients
Trial: 20130863
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative LT4 treatment among iodine-sufficient patients
Trial: 18397716
Drug: Oral mizoribine
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mizoribine (MZB) pulse therapy, 10.0-19.7 mg/kg/d, maximum total dose 750 mg, given twice a week before a meal
Trial: 18397716
Drug: Oral mizoribine
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mizoribine (MZB) pulse therapy
Trial: 15850469
Drug: peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alpha-2b 1.5 mcg/kg plus oral ribavirin (1000 or 1200 mg/day)
Trial: 7598771
Drug: rgp160 booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rgp160 booster injections
Trial: 2164070
Drug: 2% lonapalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lonapalene ointment
Trial: 30888959
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy for 23 months following one-month dual antiplatelet therapy (DAPT)
Trial: 26089029
Drug: Cinacalcet (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (60 mg)
Trial: 26089029
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg)
Trial: 16839698
Drug: Enhanced Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Therapy group (n=27) with MEMS feedback and compliance enhancement counseling using CBT techniques
Trial: 16839698
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care group (n=28) receiving weekly individual smoking cessation sessions only
Trial: 15611571
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (testosterone enanthate, 600 mg/wk intramuscularly)
Trial: 15611571
Drug: Acyline (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyline (GnRH antagonist)
Trial: 9003858
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (50 mg/day)
Trial: 30036166
Drug: Home Telemonitoring
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home Telemonitoring (HTM) with weekly video televisits and daily vital sign monitoring
Trial: 30036166
Drug: Comprehensive Outpatient
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Outpatient Management (COM) with weekly telephone contact
Trial: 29374412
Drug: Positive FIT
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive FIT results (cut-off 100 ng/mL)
Trial: 26529073
Drug: Tdap (tetanus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap (tetanus, diphtheria acellular pertussis) vaccine
Trial: 26529073
Drug: Tetanus only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus only vaccine (Control)
Trial: 12757067
Drug: Morphine 0.3
RxNorm normalized name: ethylmorphine 0.32 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.3 mg in normal saline 0.3 ml
Trial: 12757067
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.3 ml
Trial: 8883232
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg dolasetron mesilate
Trial: 8883232
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg dolasetron mesilate
Trial: 8883232
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg dolasetron mesilate
Trial: 8883232
Drug: Dolasetron mesilate
RxNorm normalized name: Dolasetron mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron mesilate (all doses pooled)
Trial: 1589561
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of sCT
Trial: 28385659
Drug: Semaglutide 0.5
RxNorm normalized name: semaglutide 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 0.5 mg once weekly
Trial: 28385659
Drug: Semaglutide 1.0
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1.0 mg once weekly
Trial: 19730273
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for suicide prevention (CBT-SP)
Trial: 15318465
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 2.5 microg kg(‐1) during induction (Groups 2 and 4)
Trial: 15318465
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution during induction (Groups 1 and 3)
Trial: 3602017
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bendroflumethiazide plus 15 mmol potassium chloride
Trial: 27421987
Drug: functionally orientated
RxNorm normalized name: Papaver orientale seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: functionally orientated treatment (SDA)
Trial: 27421987
Drug: Dental implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implant treatment
Trial: 20843224
Drug: 0.2 µg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 µg/kg/hr
Trial: 20843224
Drug: 0.4 µg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 µg/kg/hr
Trial: 12617332
Drug: Isovolemic phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isovolemic phase with sequential ultra‐filtration (ISO GROUP)
Trial: 7491878
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (17.85 mmol (714 mg)/d)
Trial: 6267617
Drug: Pivmecillinam/pivampicillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam/pivampicillin (200 mg pivmecillinam and 250 mg pivampicillin, twice daily for 10 days)
Trial: 6267617
Drug: Co-trimoxazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim, twice daily for 10 days)
Trial: 27505611
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg dried ginger capsules twice daily
Trial: 8595643
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg once daily (titrated to 10 mg after 4 weeks)
Trial: 2914082
Drug: Potassium (KCl;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium (KCl; 20 mEq three times daily)
Trial: 2914082
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (Ca; 500 mg twice daily)
Trial: 30582240
Drug: Cisplatin, fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, fluorouracil, and docetaxel followed by concurrent chemoradiotherapy
Trial: 25487930
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.05-0.1 µg·kg‐1·min‐1)
Trial: 19484483
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) every 28 days with high-dose radiotherapy
Trial: 19484483
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) every 28 days with reduced-dose radiotherapy
Trial: 18728281
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors or ARBs initiated during the study
Trial: 12072043
Drug: Oestrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen supplementation (oestradiol valerate 1 mg daily, n = 7)
Trial: 29775119
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy and diabetic diet regime
Trial: 25208464
Drug: Benralizumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (100 mg subcutaneously every 4 weeks for three doses, then every 8 weeks for five doses over 48 weeks)
Trial: 19354088
Drug: Atropine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (2.0 mg intramuscularly) at rest (T1)
Trial: 11356434
Drug: Carvedilol 6.25
RxNorm normalized name: carvedilol 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25 mg, increased to a maximum of 25 mg twice daily
Trial: 7802299
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at incremental rates (30, 60, and 120 micrograms.kg‐1.min‐1)
Trial: 466336
Drug: Gutter treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gutter treatment for ingrowing toenails
Trial: 28992899
Drug: Online cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive-behavioral therapy (CBT) plus three therapist support calls
Trial: 28992899
Drug: Online cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive-behavioral therapy (CBT) without therapist support calls
Trial: 25882864
Drug: Natriuretic peptide
RxNorm normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natriuretic peptide receptor type C mRNA expression
Trial: 25882864
Drug: Natriuretic peptide
RxNorm normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natriuretic peptide receptor type A mRNA expression
Trial: 24062325
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical care (CC)
Trial: 20864417
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (90-minute infusion)
Trial: 19407805
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at bedtime (100 mg/day)
Trial: 19407805
Drug: Aspirin on
RxNorm normalized name: Aspirin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin on awakening (100 mg/day)
Trial: 15128894
Drug: Concomitant cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant cisplatin (100 mg/m² on days 1, 22, and 43) with radiotherapy (66 Gy over 6.5 weeks)
Trial: 11922401
Drug: Ebastine 10
RxNorm normalized name: ebastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10 mg, 20 mg, 30 mg
Trial: 8104017
Drug: Triprolidine 10
RxNorm normalized name: phenylephrine HCl/triprolidine 10 mg-2.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 10 mg
Trial: 320827
Drug: Lofepramine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofepramine (70 mg t.i.d.)
Trial: 320827
Drug: Imipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50 mg t.i.d.)
Trial: 19335936
Drug: Intravenous synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous synthetic THC (2.5 mg)
Trial: 16750125
Drug: One drug
RxNorm normalized name: mometasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drug taken at bedtime
Trial: 16750125
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs taken in the morning
Trial: 15280529
Drug: Pre-emptive treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive treatment (angioplasty and/or open surgery)
Trial: 11315820
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in premeal insulin dose
Trial: 9134643
Drug: High-intensity coumarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity coumarin therapy
Trial: 9134643
Drug: Low-intensity coumarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity coumarin therapy
Trial: 15472191
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg/d
Trial: 8185424
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 1.25 mg/d
Trial: 26291918
Drug: 0.50% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50% DHEA (prasterone) ovules administered intravaginally daily for 12 weeks
Trial: 23599120
Drug: 3 to
RxNorm normalized name: Melquin-3 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 12 mg kg(‐1) per day of iron supplementation based on the ZnPP/H
Trial: 23599120
Drug: 2.2 mg
RxNorm normalized name: menthol 2.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 mg kg(‐1) per day of ferrous sulfate (control)
Trial: 21883322
Drug: AST-120 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 2 g tds
Trial: 8230988
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) administered intravenously (dose 100 m/kg b.w.)
Trial: 7380201
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme therapy
Trial: 3633631
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no pancreatic enzyme therapy)
Trial: 31682878
Drug: SM-VAP patients
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-VAP patients receiving early adequate therapy (n=70, 68.6%)
Trial: 31682878
Drug: Adequate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate treatment (monotherapy or combination of antimicrobials)
Trial: 26803589
Drug: Low-carbohydrate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate diet (carbohydrate <40 g/day)
Trial: 20051257
Drug: Wujijing Oral
RxNorm normalized name: influenza B virus B/Hubei Wujigang/158/2009/antigen
DrugBank: Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated) (DB10780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wujijing Oral Liquid (WJJ) 10mL twice daily for 2 menstrual cycles
Trial: 18038179
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser therapy (810 nm)
Trial: 18038179
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) therapy
Trial: 12759802
Drug: All antipsychotic
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antipsychotic medications
Trial: 10553856
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg succinylcholine
Trial: 8688343
Drug: Active pastilles
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pastilles containing amphotericin, polymyxin and tobramycin, suck four times daily
Trial: 25864623
Drug: Marine omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine omega-3 fatty acids (Omacor(®) fish oil, 1 g/d)
Trial: 21987240
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin 400 mg
Trial: 21987240
Drug: Intravenous moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxifloxacin 400 mg
Trial: 15905296
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus flutamide (62.5 mg/day)
Trial: 15905296
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception (OC) monotherapy
Trial: 15905296
Drug: Oral contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception plus flutamide-metformin
Trial: 12569142
Drug: 9-cis-retinoic acid
RxNorm normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-cis-retinoic acid (100 mg daily for 3 months)
Trial: 12569142
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid (1 mg/kg) + alpha-tocopherol (1200 IU) for 3 months
Trial: 1759096
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tincture of belladonna (0.01 mg/kg weight of atropine)
Trial: 1759096
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup containing no belladonna
Trial: 31773209
Drug: Cherry flavored
RxNorm normalized name: Syrspend SF Cherry Flavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cherry flavored e-liquid (24 mg/ml)
Trial: 31773209
Drug: Vanilla flavored
RxNorm normalized name: OCTINOXATE 3.6 g in 1 g / OCTISALATE 2.5 g in 1 g / OXYBENZONE 1.5 g in 1 g TOPICAL LIPSTICK [Lip Balm Vanilla Flavored]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanilla flavored e-liquid (24 mg/ml)
Trial: 31773209
Drug: Menthol flavored
RxNorm normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol flavored e-liquid (24 mg/ml)